HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Helicobacter Pylori Diagnostics Market Size and Share Analysis - 2026 To 2033

The Helicobacter Pylori Diagnostics market is anticipated to grow at a CAGR of 10.04% with USD 981.87 Mn in 2026 and is expected to reach USD 1.95 Mn in 2033. The market growth is fueled by the push for decentralized testing capabilities, enhanced surveillance for antimicrobial resistance, and greater diagnostic testing in outpatient environments. Investments in modern diagnostics in line with high awareness and autonomy in gastrointestinal disease management (600 Mn), enabling providers to meet shifting patient and payer expectations.

Key Takeaways

• Non-invasive is expected to account the largest share of 60% in 2026, as non-invasive tests are painless as well as simpler than endoscopy. Ultrasound in Obstetrics & Gynecology (UOG) achieved another impressive 6.3 Mn downloads in 2025.
• The hospitals segment will dominate with 55% in 2026, hospitals see more patients with gastrointestinal complaints needing H. pylori testing. India's 2025 hospital statistics 23582 government hospitals, and 29899 PHCs.
• Asia Pacific is expected to acquire the dominant share of 45% in 2026, Countries like China, India, Japan, and Southeast Asia have much higher infection rates than Western countries. In the SEA Region during weeks 48-50, there were 314 influenza positive samples from 1 723 samples tested, with an overall positivity rate of 18%. Bhutan and Thailand reported relatively high test positive proportion, with 41% and 31%, respectively.

Segmental Insights 

Why is Non-invasive Segment Acquiring the Largest Market Share?

Non-invasive segment is projected to account for the largest share of test type in 2026, representing approximately 60% of the total volume. Its superior patient acceptance, cost-effectiveness, as well as accessibility across diverse healthcare settings are the factors responsible for the growth of the segment. If current practices continue, CT scan use might eventually account for about 5% of all new cancer diagnoses in the U.S. per year.

The high adoption of breath tests, particularly the urea breath test (UBT), which has been promoted by the American College of Gastroenterology and the European Helicobacter and Microbiota Study Group as the gold standard for H. pylori detection in many clinical scenarios is fueling the market. For example, the C13-urea breath test has demonstrated exceptional accuracy rates and has become the preferred initial diagnostic approach in countries like Germany, where healthcare authorities have connected it into standard gastroenterology protocols.

Hospitals holds the Largest Market Share  

Based on End Users, hospitals dominate the market, accounting for a significant 55% share in 2026, their overall infrastructure, advanced diagnostic capabilities, as well as established patient care pathways are the factors responsible for the growth of the segment.

The total number of hospitals globally estimated to reach ≈215,977 by 2026 choosing the right institution has profound consequences for Patient Outcomes and Healthcare.

Hospitals maintain sophisticated laboratory facilities equipped with state-of-the-art diagnostic equipment including endoscopy units, rapid antigen testing systems, molecular diagnostic platforms, etc., that enable accurate and timely detection of H. pylori infections.

The connection of multiple diagnostic modalities within hospital settings allows for immediate correlation of clinical symptoms with laboratory findings, facilitating prompt treatment decisions.

Rapid Urease Test (RUT) Technologies is transforming the Helicobacter Pylori Diagnostics Industry

New rapid urease tests use better pH indicators as well as incubation systems to detect H. pylori faster and more accurately. Key companies using these technologies include Kimberly-Clark (CLOtest), Meridian Bioscience (Premier Platinum HpSA), and Sekisui Diagnostics (Pyloritek), which offers results in just 1 hour.

Adopting these tests reduces diagnosis time from 24 hours to 1–3 hours and improves accuracy from 85% to 95%. Hospitals and endoscopy units advance from higher patient throughput as well as lower costs, saving 30–40% compared to older methods.

Molecular Diagnostics for Biopsy Samples: A major breakthrough in Helicobacter Pylori Diagnostics

New molecular tests leverage real-time PCR along with next-generation sequencing (NGS) to find H. pylori DNA and antibiotic resistance genes in biopsy samples. Companies utilizing these technologies include Roche Diagnostics (cobas Hp test), BD (BD MAX system), bioMerieux (FilmArray GI Panel), Quidel Corporation (AmpliVue H. pylori assay), etc.

These tests are very particular, with sensitivity over 98%, as well as they can check for antibiotic resistance at the same time. Results come faster, in 2–4 hours, which helps doctors give personalized treatment. This approach improves first-line treatment success rates by about 25%.

Current Events and Their Impact on the Helicobacter Pylori Diagnostics Market

Helicobacter Pylori Diagnostics Market Trends

• Growing preference for breath tests, stool antigen tests, as well as serological tests over invasive endoscopic procedures. An independent analysis of police breath testing data found more than 42,000 "irregular" breath tests, 12,000 more than initially believed.
• High demand for rapid, decentralized diagnostic solutions in primary care settings
• Adoption of AI-powered diagnostic tools and telemedicine platforms for remote testing as well as consultation. According to a study done by Roche, the telehealth industry is projected to grow significantly, surpassed USD 55 billion by the end of 2025.
• Development of antibiotic susceptibility testing to cater to the rising antimicrobial resistance

Regional Insights 

Asia Pacific dominates owing to the region's substantial burden of Helicobacter pylori infections

Asia Pacific account 45% market share in 2026, the region's substantial burden of Helicobacter pylori infections and the comprehensive healthcare infrastructure developments across major economies. Asia accounts for 70% of the global gastric cancer burden, due to its massive population and high prevalence of Helicobacter pylori infection.

The exceptionally high prevalence rates of H. pylori infections across diverse populations is another growth inducing factor. According to the World Health Organization's regional data, countries like China, India, Japan, South Korea, etc., show infection rates ranging from 40% to 70% of their populations, majorly higher than global averages.

North America Helicobacter Pylori Diagnostics Market Trends

The North America region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 6.2%. Driven by unprecedented domestic innovation along with increasing healthcare infrastructure investments. The United States spends USD 14 885 per capita on health, more than the OECD average of $5 967 (USD PPP).

The National Institutes of Health (NIH) has reported a high surge in federally funded research grants specifically targeting H. pylori diagnostic advancement, with over 150 new research projects initiated between 2022 and 2024 across leading academic medical centers including Mayo Clinic, Johns Hopkins, as well as Cleveland Clinic.

This domestic research momentum has catalyzed the development of novel point-of-care testing solutions that are uniquely adapted to North American healthcare delivery models. The American Medical Association's recent guidelines emphasizing early H. pylori detection have prompted high adoption of advanced diagnostic protocols across primary care settings, particularly in rural as well as underserved communities where traditional endoscopic procedures are less accessible.

Robust Healthcare Infrastructure Development is Accelerating the Helicobacter Pylori Diagnostics Market Demand in China

The China contribute highest share in market owning to its robust healthcare infrastructure development, extensive population base requiring comprehensive H. pylori screening programs, and significant government investments in diagnostic technologies. In 2025, China's primary-level healthcare institutions handled 5.56 billion patient visits, accounting for 52.6% of all medical visits to the country's medical facilities.

The massive healthcare modernization initiative of the country, supported by the National Health Commission, has led to widespread adoption of advanced diagnostic equipment across tier-one and tier-two cities.

U.S. Helicobacter Pylori Diagnostics Market Trends

The U.S. contributes the highest share in the Helicobacter Pylori diagnostics market in North America owing to its overall healthcare infrastructure, advanced diagnostic capabilities, and significant prevalence of H. pylori infections across diverse population groups. H. pylori are present in 30% to 40% of the North American population.

Emphasis of the U.S. healthcare system on preventive care and early detection has driven substantial adoption of H. pylori diagnostic testing, particularly given the bacterium's strong association with peptic ulcers and gastric cancer.

According to the Centers for Disease Control and Prevention (CDC), approximately 35% of Americans are infected with H. pylori, with higher prevalence rates observed among Hispanic Americans (62%) and African Americans (54%) compared to Caucasian Americans (26%). This demographic diversity necessitates robust diagnostic infrastructure, which the U.S. has successfully developed through its network of hospitals, clinical laboratories, and specialized gastroenterology centers.

Who are the Major Companies in Helicobacter Pylori Diagnostics Industry

Some of the major key players in Helicobacter Pylori Diagnostics market include, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd. (Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.

Key News

• In April 2025, the International Agency for Research on Cancer (IARC) provides recommendations for implementing population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention.
• In February 2026, Nitazoxanide-based regimens demonstrated improved H pylori eradication rates relative to standard triple therapy (risk ratio [RR], 1.36; 95% CI, 1.19-1.56; I2, 0%; P <.0001).

Market Report Scope 

Analyst Opinion

• The Helicobacter pylori diagnostics market demonstrates robust expansion potential, driven by rising global prevalence of peptic ulcers and gastric cancer cases linked to H. pylori infections. Peptic ulcer disease (PUD) is a global problem with a lifetime risk of development ranging from 5% to 10%.
• Increasing awareness among healthcare professionals regarding the critical role of early detection in preventing severe gastrointestinal complications serves as a primary market catalyst.
• The growing adoption of advanced diagnostic techniques, including rapid urease tests, molecular diagnostics, and breath testing methodologies, significantly enhances diagnostic accuracy and patient convenience. Ninety-eight (35.00%) out of 280 patients were diagnosed with H. pylori infection by at least one diagnostic test used in the study.
• Additionally, varying regulatory approval processes across different countries create implementation challenges for diagnostic manufacturers seeking global market penetration.
• The market presents substantial opportunities through technological innovations in point-of-care testing solutions and development of non-invasive diagnostic alternatives. In January 2025, Plain Radiography (X-ray) was most common (1.88 million), followed by Diagnostic Ultrasonography (Ultrasound, 0.95 million).

Market Segmentation

• By Test Type (Revenue, USD Mn, 2021-2033)
  • Invasive
    • Immunoassay
    • Rapid Urease Test
    • Histology
  • Non-invasive
    • Stool Antigen Assay
    • Serology Tests
    • Urea Breath Test
• By End Users (Revenue, USD Mn, 2021-2033)
  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Medical Device Manufacturers
• Clinical Laboratory Directors
• Gastroenterologists and Healthcare Practitioners
• Diagnostic Kit Distributors
• Others

Databases

• WHO Global Health Observatory
• FDA Medical Device Database
• PubMed/MEDLINE
• Others

Magazines

• Medical Device & Diagnostic Industry (MD+DI)
• Laboratory Equipment Magazine
• Clinical Laboratory News
• Point of Care Magazine
• Others

Journals

• Journal of Clinical Microbiology
• Helicobacter Journal
• Diagnostic Microbiology and Infectious Disease
• Others

Newspapers

• The Wall Street Journal
• Financial Times
• Bloomberg Healthcare
• Others

Associations

• American Gastroenterological Association (AGA)
• Clinical Laboratory Management Association (CLMA)
• American Society for Microbiology (ASM)
• International Association of Medical Laboratory Technologists
• Others

Public Domain Sources

• CDC (Centers for Disease Control and Prevention)
• NIH (National Institutes of Health)
• European Centre for Disease Prevention and Control (ECDC)
• World Gastroenterology Organisation
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years